- Sino Biological completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock closed 68% higher at a market capitalization of $5.2 billion.
- Beijing InnoCare in-licensed greater China rights to a CD19 targeting mAb from Delaware-based Incyte in a $117.5 million agreement.
- Gracell Bio, a Suzhou CAR-T company, acquired rights to FutureGen's CLDN18.2 antibodies, which it will use to develop novel immune cell therapies for solid tumors.
- Suzhou Innovent Bio reported that its PD-1 inhibitor met an overall survival endpoint in a Phase III trial as a first-line treatment for gastric cancer.
For further details see:
Week In Review: Sino Biological Stages $772 Million IPO On ChiNext Exchange